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Abstract
Background: Shared decision-making is a cornerstone of patient-centred care. The 9-item Shared Decision-Making
Questionnaire (SDM-Q-9) is a brief self-assessment tool for measuring patients’ perceived level of involvement in
decision-making related to their own treatment and care. Information related to the psychometric properties of the
SDM-Q-9 for multiple sclerosis (MS) patients is limited. The objective of this study was to assess the performance of
the items composing the SDM-Q-9 and its dimensional structure in patients with relapsing-remitting MS.
Methods: A non-interventional, cross-sectional study in adult patients with relapsing-remitting MS was conducted
in 17 MS units throughout Spain. A nonparametric item response theory (IRT) analysis was used to assess the latent
construct and dimensional structure underlying the observed responses. A parametric IRT model, General Partial
Credit Model, was fitted to obtain estimates of the relationship between the latent construct and item
characteristics. The unidimensionality of the SDM-Q-9 instrument was assessed by confirmatory factor analysis.
Results: A total of 221 patients were studied (mean age = 42.1 ± 9.9 years, 68.3% female). Median Expanded
Disability Status Scale score was 2.5 ± 1.5. Most patients reported taking part in each step of the decision-making
process. Internal reliability of the instrument was high (Cronbach’s α = 0.91) and the overall scale scalability score
was 0.57, indicative of a strong scale. All items, except for the item 1, showed scalability indices higher than 0.30.
Four items (items 6 through to 9) conveyed more than half of the SDM-Q-9 overall information (67.3%). The
SDM-Q-9 was a good fit for a unidimensional latent structure (comparative fit index = 0.98, root-mean-square error
of approximation = 0.07). All freely estimated parameters were statistically significant (P < 0.001). All items presented
standardized parameter estimates with salient loadings (>0.40) with the exception of item 1 which presented the
lowest loading (0.26). Items 6 through to 8 were the most relevant items for shared decision-making.
Conclusions: The SDM-Q-9 presents appropriate psychometric properties and is therefore useful for assessing
different aspects of shared decision-making in patients with multiple sclerosis.
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Background
The shared decision-making (SDM) is rooted in the
ethical concept of bidirectional communication between
patients and clinicians to reach agreements related to
therapeutic issues. The basis for SDM is the principle of
respecting individuals’ autonomy and their involvement
in the discussion of available therapeutic options [1, 2].
Furthermore, SDM incorporates both patient values and
preferences as well as the best available evidence related
to treatment efficacy and safety. The goal of SDM is to
improve the quality of patient care, health outcomes, and
treatment adherence. A direct relationship between im-
proved SDM quality and enhanced satisfaction with health
care decisions has been previously documented [3].
Treatment decisions in multiple sclerosis (MS) are
becoming more challenging due to increasingly diverse
risk-benefit spectrum associated with the new disease-
modifying therapies (DMTs) and the lack of reliable
treatment response biomarkers [4, 5]. A more proactive
management strategy, including earlier use of high-
efficacy DMTs and close monitoring of the clinical and
radiological response to treatment, is recommended to
slow the progression of physical and cognitive impair-
ments in patients with relapsing-remitting MS (RRMS)
[6]. In this context, SDM may be a valuable tool in the
clinical care of MS [7].
There are several instruments available to assess SDM
in a clinical setting [8]. One of the most frequently used
instruments is the 9-item Shared Decision-Making
Questionnaire (SDM-Q-9), that has been translated and
validated in Spanish amongst other languages [9, 10].
However, little is known about its psychometric proper-
ties in MS patients who must decide among alternative
therapeutic options. Accordingly, and to generalize its
application, the SDM-Q-9 was assessed in a population
of patients with relapsing-remitting multiple sclerosis
(RRMS). The aims of this study were to assess the psy-
chometric performance of the items composing the
SDM-Q-9 by item response theory (IRT) analysis, and
to assess the unidimensionality of the instrument by
confirmatory factor analysis (CFA).
Methods
A non-interventional, cross-sectional study to assess
patients’ preferences for a range of disease-modifying
therapy attributes was conducted in 17 MS units
throughout Spain (the EMPOWER study) [11]. Patients
with the following inclusion criteria were enrolled in
the study: (i) age ≥ 18 years, (ii) a diagnosis of RRMS
according to McDonald 2010 criteria, (iii) currently
receiving a DMT (at least during the previous three
months), and (iv) an Expanded Disability Status Scale
(EDSS) score of 1 to 6 points [12, 13]. Written in-
formed consent was obtained from all subjects. The
study was approved by the institutional review board of
the Hospital Universitari Dr. Josep Trueta (Girona, Spain)
and conducted between January and March 2016.
We performed a post hoc analysis using data from the
aforementioned study in order to assess the psychometric
performance of the SDM-Q-9. The SDM-Q-9 instrument
was developed to assess the patient subjective experience
of SDM according to nine stages on the decision-making
process [9]. It describes the experience of SDM through
nine items which are scored on a six-point Likert scale
from 0 (completely disagree) to 5 (completely agree).
Summing up all items leads to a raw total score between 0
and 45. As suggested we performed a linear transformation
of the scale to provide a transformed score range from 0 to
100, with higher values indicating greater extent of SDM.
The SDM-Q-9 has been shown to have high internal
consistency, validity, and a unidimensional structure for
the underlying construct it claims to measure [9]. Its main
use is in studies investigating the effectiveness of interven-
tions aimed at the implementation of SDM and as a quality
indicator in health services assessments. We used the
Spanish validated version of the SDM-Q-9 instrument [10].
Statistical analyses
For continuous data, descriptive statistics were expressed
as mean and standard deviation (SD), or median and
interquartile range (IQR). For categorical data, descrip-
tive statistics were expressed as frequencies and percent-
ages. For description and comparison with other studies,
and to aid the interpretation of the scoring, SDM-Q-9
scores were linearly transformed from the numerical value
(0 to 5) to a percentage of the maximum score (0 = no
SDM behaviour; 100 = ideal SDM behaviour) as suggested
by the original authors of the scale [9]. However, for IRT
and CFA the covariance matrix of raw scores were
analyzed (range of 1 to 6).
A nonparametric IRT analysis (Mokken analysis) was
used to assess the latent construct and dimensional
structure underlying the association matrix of observed
responses [14, 15]. Two Mokken models were fitted: the
monotone homogeneity model and the double mono-
tonicity model. The monotone homogeneity model
tested the validity of a scale total score for ordering and
classifying subjects according to the degree of the con-
struct exhibited. The double monotonicity model was a
more restrictive model in that it identified whether an
order existed among the items and rated the corre-
sponding construct that was independent of the selected
sample. The Mokken results were interpreted according
to the following rules: to be considered relevant, all items
were required to have a scalability coefficient (Hi) ≥ 0.30,
and the total scale was required to have a scalability coeffi-
cient (H) ≥ 0.30. Mokken suggested the following thresholds
for interpreting scalability coefficients for a measurement
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scale: weak scale 0.3 ≤H < 0.4; medium scale 0.4 ≤H < 0.5;
and strong scale H ≥ 0.5 [14]. The internal reliability of the
SDM-Q-9 scale was evaluated according to both Cronbach
and Mokken estimates.
A parametric IRT model, the General Partial Credit
Model (GPCM) was fitted to obtain estimates of the
relationship between the latent construct and the item
characteristics [16]. Specifically, the item response
characteristic curve parameters (ICC) and the item
information were estimated to assess the discrimination
among category thresholds, and the measurement precision
of the trait of each item, respectively.
Finally, the dimensionality of the SDM-Q-9 was assessed
by confirmatory factor analysis (CFA). Goodness-of-fit for
the CFA was evaluated using the comparative fit index
(CFI) that evaluates the fit of a user-specified solution in
relation to a more restricted, nested baseline model (null
model), and the root-mean-square error of approximation
(RMSEA) that assesses the extent to which a model
reasonably fits in the population. A value of CFI > 0.95
was considered as an acceptable model fit, a RMSEA
value < 0.08 was considered to reflect an adequate fit to
the model, and a RMSEA value < 0.05 was considered as a
good fit [17].
The statistical program R v3.3.1 with the libraries
“mokken”, “ltm”, and “lavaan” was used to perform the
statistical analyses [18–21].
Results
A total of 221 patients were included in the study.
Patients were predominantly female (68.3%) with a mean
age of 42.1 ± 9.9 years. The mean time elapsed since
diagnosis was 9 years and the median EDSS score was 2.5
± 1.5. The most common current DMTs were first-line
injectable therapies (43.9% of patients), followed by fingo-
limod (19.0%), dimethyl fumarate (15.4%), and natalizu-
mab (12.2%). The main socio-demographic and clinical
characteristics of the sample are presented in Table 1.
Median overall SDM-Q-9 score among the patients was
93.3% (IQR = 80-100%). The maximum SDM-Q-9 score
was given by 62 (28%) of the patients. All SDM-Q-9 items
scored high with maximum scores ranging from 54.3%
(item 8:”My doctor and I selected a treatment option
together”) to 77.1% (item 3:”My doctor told me that there
are different options for treating my medical condition”).
Internal reliability
The Cronbach’s α reliability coefficient was 0.91 (95%
confidence boundaries = 0.89 to 0.93), and the Mokken
reliability was 0.92.
Non-parametric (Mokken) IRT
Table 2 shows the endorsement frequencies and Mokken
scalability indices for the SDM-Q-9 items. All items
were well-fitting for the unidimensional scale with the
exception of item 1 (“My doctor made clear that a
decision needs to be made”). Likewise, all items showed
scalability indices (Hi) over 0.30, except for item 1. The
scalability for the overall scale (H) was 0.57 indicative of
a strong scale according to Mokken’s criteria. The SDM-
Q-9 scale well-fitted the Mokken monotonicity model
with different item discrimination (no assumption viola-
tions were found), but not to the double monotonicity
model which showed a large number of assumption vio-
lations for all items.
Item characteristics: GPCM
Table 3 shows the parameters estimated by GPCM.
More than half (67.3%) of the SDM-Q-9 overall informa-
tion was conveyed by four items: item 7 (“My doctor and
I thoroughly weighed the different treatment options”),
item 8, item 6 (“My doctor asked me which treatment
option I prefer”), and item 9 (“My doctor and I reached
an agreement on how to proceed”). The least amount of
information was conveyed by item 1 (1.5%). Figure 1
displays the ICC. Most items presented a shape and
category threshold compatible with appropriate difficulty
and discrimination parameters. As before, the main
exception was item 1 which did not present a good
behaviour.
Factor structure
The SDM-Q-9 results well-fitted a unidimensional latent
structure (CFI = 0.98, RMSEA = 0.07). Inspection of stan-
dardized residuals and modification indexes indicated no
Table 1 Main characteristics of the sample
N = 221
Age, mean (SD) 42.1 (9.9)
Gender. Female, n (%) 151 (68.3%)
Employment status, n (%) Employed (part-time or
full-time)
115 (52.0%)
Unemployed 28 (12.7%)
Retired due to MS 41 (18.6%)
Retired due to other reasons 6 (2.78%)
Without paid employment 31 (14.0%)
Some level of incapacity for work, n (%) 75 (34.9%)
Time of MS evolution (years), mean (SD) 9.1 (6.9)
EDSS score, median (SD) 2.5 (1.5)
Time with DMT treatment (years), mean (SD) 6.0 (4.4)
Use of previous DMT treatment, n (%) 133 (60.2%)
Presence of relapses, n (%) Since diagnosis 201 (91.0%)
During the last 2 years 100 (45.2%)
During the last year 52 (23.5%)
DMT: Disease-modifying treatment; EDSS: Expanded Disability Status Scale; MS:
multiple sclerosis
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localized points of ill fit in the final solution with the
exception of including correlated measurement error
between some items (items 1 and 2; item 3 with items 4, 8
and 9; item 4 and 5; and item 5 and 9). All freely estimated
unstandardized parameters were statistically significant
(p < 0.001). Table 3 shows the standardized parameter
estimates (factor loadings) for all items, all of which
had salient loadings (>0.40), except for item 1 which
had a salient loading of 0.26 and presented the lowest
loading of all items. Items 6, 7 and 8 were the more
related within the construct of SDM.
Discussion
This study reports the psychometric properties of the
SDM-Q-9 in a sample of patients with RRMS. Our
results show that the SDM-Q-9 instrument is a worth-
while and feasible tool to elicit SDM in patients receiv-
ing treatment for MS. With the exception of item 1, the
rest of the items of the scale fit to a unidimensional and
strong structure according to Mokken criteria. The
unidimensional structure of the instrument was also
confirmed by CFA where all items (except for item 1)
presented salient loadings (>0.40) within the construct
of SDM. Furthermore, the internal reliability of the scale
was high (Cronbach’s α = 0.91) and consistent with the
range 0.88 to 0.94 found in other studies [9, 10, 22, 23].
Our results confirm previous observations of the
SDM-Q-9 instrument which indicated that item 1 (“rec-
ognizing that a decision needs to be maden) did not
present good psychometric properties and behaved dif-
ferently from the rest of the items [9, 10, 22]. Item 1
had: (i) the lowest Mokken scalability index (Hi = 0.27)
in an otherwise strong scale (H = 0.57); (ii) the lowest
standardized CFA loading (0.26) - far from the usual cri-
terion of salient loading with the underlying construct
(values ≥ 0.40) which is achieved by the rest of the SDM-
Q-9 items –; and (iii) the lowest discrimination param-
eter and information according to the IRT analysis. In
fact, other studies have demonstrated that the fitting of
the CFA analyses to a unidimensional structure improved
when item 1 was excluded from the solution [6, 24]. It is
likely that by modifying the content of the wording of the
Table 2 Endorsement frequencies and Mokken scalability (Loevinger’s Hi coefficients) for the 9 items of the Shared Decision-Making
Questionnaire (SDM-Q-9)
Item number and content Mean (SD) Endorsement frequencies (%) Hi
1 2 3 4 5 6
1. A decision needs to be made 5.19 (1.37) 14 (6) 4 (2) 3 (0.01) 18 (0.08) 49 (0.22) 135 (0.60) 0.27
2. How I want to be involved 5.17 (1.23) 7 (3) 5 (2) 7 (0.03) 31 (0.14) 46 (0.21) 127 (0.57) 0.60
3. Informing me different options are available 5.53 (1.12) 8 (4) 2 (1) 4 (0.02) 8 (0.04) 29 (0.13) 172 (0.77) 0.58
4. Explaining me advantages and disadvantages 5.57 (1.00) 5 (2) 2 (1) 3 (0.01) 12 (0.05) 31 (0.14) 170 (0.76) 0.59
5. Helping me to understand the information 5.63 (0.86) 4 (2) 0 (0) 2 (0.01) 10 (0.04) 37 (0.17) 170 (0.76) 0.54
6. Asking the treatment option I prefer 5.07 (1.46) 12 (5) 10 (4) 10 (0.04) 19 (0.08) 40 (0.18) 132 (0.59) 0.63
7. Weighing jointly the different options 5.13 (1.37) 11 (5) 8 (4) 4 (0.02) 25 (0.11) 46 (0.21) 129 (0.58) 0.66
8. Selecting a treatment option together 5.04 (1.41) 13 (6) 7 (3) 6 (0.03) 28 (0.13) 48 (0.21) 121 (0.54) 0.66
9. Agreeing on how to proceed 5.30 (1.23) 7 (3) 8 (4) 5 (0.02) 10 (0.04) 53 (0.24) 140 (0.63) 0.61
The overall scalability (H) is 0.57. Endorsement frequencies: 1 completely disagree; 2 strongly disagree; 3 somewhat disagree; 4 somewhat agree; 5 strongly agree;
6 completely agree
Table 3 General Partial Credit Model (GPCM) parameters, and standardised loadings from confirmatory factor analysis for the 9-item
Shared Decision-Making Questionnaire (SDM-Q-9)
Item no. a b1 b2 b3 b4 b5 Information CFA loadings
1 0.22 4.50 0.42 −8.60 −4.83 −4.62 1.10 0.26
2 1.16 −1.73 −1.97 −2.59 −1.14 −0.93 5.80 0.72
3 1.34 −1.09 −2.40 −2.12 −2.14 −1.73 6.71 0.75
4 1.28 −1.51 −2.25 −2.72 −1.93 −1.73 6.40 0.67
5 1.15 −1.57 NA −3.13 −2.36 −1.73 4.62 0.55
6 1.90 −1.83 −1.59 −1.61 −1.25 −0.74 9.48 0.87
7 3.41 −1.97 −1.53 −1.92 −1.18 −0.50 17.03 0.92
8 3.33 −1.83 −1.60 −1.79 −1.08 −0.39 16.66 0.92
9 1.52 −2.17 −1.48 −1.92 −2.11 −0.85 7.62 0.76
Goodness-of-fit indices for the CFA; CFI = 0.984, RMSEA = 0.069
Note a: discrimination parameter; b’s: threshold parameters; CFA: confirmatory factor analysis
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item, its ICC shape and psychometric properties would
improve. However, we are not aware of any improvement
of this scale through content modification, probably
because of the high internal reliability attained by the
current version of the SDM-Q-9 with relatively few items.
Our study has several limitations. First, the study
population was comprised of a sample of clinically stable
patients with low disability, mostly employed and receiv-
ing their first disease-modifying therapy. The results
may thus not be generalizable to less stable subjects.
Second, it would have been interesting to assess the
absence of differential item functioning (DIF) in order to
confirm the unidimensionality of the SDM-Q-9. How-
ever, there is not enough sample size to conduct a DIF
appropriately according to classification criteria of the
EMPOWER study. Despite this limitation, the study also
has several strengths. The sample of 221 patients was
managed in 17 different MS units at national level, which
allows results to be generalised to community practice.
Shared decision-making is a cornerstone of patient-
centred care [25]. Involving MS patients in the
decision-making process is crucial for selecting the
treatment that best suits the patient’s profile and
preferences [7]. Therefore, treatment decisions in MS
should be conjointly made by the neurologist and the
patient, and should be based not only on the best
available evidence but also taking into account the
patient’s values and preferences [26, 27].
Conclusion
The SDM-Q-9 instrument showed good psychometric
properties and fitted a unidimensional latent trait related
with SDM in patients with RRMS. Further studies focus-
ing on the psychometric properties of the SDM-Q-9
instrument should be performed on representative sam-
ples of patients with other diseases benefitting from SDM
processes in order to evaluate its equivalence.
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